evaluate novo nordisk on glp-1 agonists The Battle of the Blockbusters: Glucagon-like Peptide-1 (GLP-1) Agonists Market
Description
Vomiting, diarrhea and constipation occur less frequently but still affect notable numbers of patients
-agonists-market-key-insight.png)
[DOI] [PubMed] [Google Scholar] 36
Patients should be advised that GLP-1 receptor agonists are not insulin, but some patients may need both a GLP-1 receptor agonist and insulin
A nationwide register-based cohort and self-controlled case series study
These results established tirzepatide as the most potent agent in the current pharmacologic armamentarium for obesity
